High-Dose Haemodiafiltration Compared to High-Flux Haemodialysis - EMJ

High-Dose Haemodiafiltration Boosts Survival and Quality of Life

1 Mins
Nephrology

THE CONVINCE trial has recently revealed promising results for patients undergoing high-dose haemodiafiltration (HDF) over high-flux haemodialysis (HD). Led by Matthias Rose, Center for Patient Centered Outcomes Research, Charité Universitätsmedizin Berlin, Germany, this trial aimed to identify the best possible dialysis treatment by comparing high-dose HDF versus conventional high-flux HD treatment.

The primary analysis demonstrated a clear survival benefit for patients receiving HDF. A secondheary objective of the study focused on health-related quality of life (HRQoL), which was assessed in eight domains: physical function, cognitive function, fatigue, sleep disturbance, anxiety, depression, pain interference, and social participation. These domains were measured using the Patient-Reported Outcome Measurement Information System (PROMIS) before randomisation and every three months thereafter.

In total, 1,360 adults with dialysis-dependent chronic kidney disease participated in the trial. Patients were randomly assigned to either the HDF or HD group, with an 84% response rate to the questionnaires. Both groups experienced a continuous decline in all HRQoL domains, but the deterioration was notably slower in the HDF group.

After a median observation period of 30 months, the most significant differences were seen in cognitive function. HDF patients showed a decline of -0.95 units, while HD patients experienced a steeper decline of -3.90 units. Additionally, the HDF group showed a slower decline in physical function, pain interference, and social participation. Overall, the physical health summary score for HDF patients decreased by -0.46 units per year more slowly than for HD patients.

The CONVINCE trial highlights the dual benefit of high-dose HDF, showing both improved survival and a moderate positive impact on quality of life, particularly in cognitive function.

Helena Bradbury, EMJ

 

Reference

Rose M et al. The CONVINCE randomized trial found positive effects on quality of life for patients with chronic kidney disease treated with hemodiafiltration. Kidney Int. 2024.

Rate this content's potential impact on patient outcomes

Thank you!

Please share some more information on the rating you have given